Stock RAM RAMKHAMHAENG HOSPITAL
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Ramkhamhaeng Hospital

Equities

RAM

TH0259A10Z01

End-of-day quote Thailand S.E.
Other stock markets
 06:00:00 2024-06-11 pm EDT 		5-day change 1st Jan Change
29.75 THB -1.65% Intraday chart for Ramkhamhaeng Hospital -3.25% -17.36%
May. 16 Ramkhamhaeng Hospital Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 30 Ramkhamhaeng Hospital Public Company Limited Elects Benny Lim as Director CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The company returns high margins, thereby supporting business profitability.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • With a 2024 P/E ratio at 26.33 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • With an enterprise value anticipated at 4.66 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
RAMKHAMHAENG HOSPITAL Stock Ramkhamhaeng Hospital
-17.36% 979M -
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+25.91% 89.26B
C+
CVS HEALTH CORPORATION Stock CVS Health Corporation
-24.02% 75.31B
B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+4.58% 27.41B
C+
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
+6.59% 18.36B
A-
LABCORP HOLDINGS INC. Stock Labcorp Holdings Inc.
-13.61% 16.55B
B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
+0.69% 15.42B
A-
NATERA, INC. Stock Natera, Inc.
+79.76% 13.83B
C-
PURE HEALTH HOLDING Stock Pure Health Holding
-24.91% 12.64B - -
UNIVERSAL HEALTH SERVICES, INC. Stock Universal Health Services, Inc.
+22.83% 12.53B
B-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. RAM Stock
  4. Ratings Ramkhamhaeng Hospital